AR045955A1 - Compuestos benzoimidazolicos - Google Patents
Compuestos benzoimidazolicosInfo
- Publication number
- AR045955A1 AR045955A1 ARP040103534A ARP040103534A AR045955A1 AR 045955 A1 AR045955 A1 AR 045955A1 AR P040103534 A ARP040103534 A AR P040103534A AR P040103534 A ARP040103534 A AR P040103534A AR 045955 A1 AR045955 A1 AR 045955A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- independently
- cyclic structure
- alkoxy
- assignments
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
- C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
- C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
- C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
- C04B35/632—Organic additives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2318/00—Antibody mimetics or scaffolds
- C07K2318/10—Immunoglobulin or domain(s) thereof as scaffolds for inserted non-Ig peptide sequences, e.g. for vaccination purposes
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Manufacturing & Machinery (AREA)
- Ceramic Engineering (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Structural Engineering (AREA)
- Inorganic Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Materials Engineering (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Compuestos benzoimidazólicos, composiciones y métodos para usarlos en la inhibición del reclutamiento de leucocitos, en la modulación del receptor H4 y en el tratamiento de afecciones tales como inflamación, afecciones mediadas por el receptor H4 y afecciones relacionadas. Reivindicación 1: Un compuesto de fórmula (1) o (2), en las cuales: W es N o CR7; X es N o CH; Y es O, NR12 o CR12R13; Z es N o CR14; n es 0, 1 ó 2; cada uno de R1-4 es, independientemente de otras asignaciones de sustituyentes, H, alquilo C1-4, alquenilo C2-5, alquinilo C2-5, cicloalquilo C3-6, alcoxi C1-4, alquilamino C1-4, alquiltio C1-4, alquilsulfonilo C1-4, -Ocicloalquilo C3-6, -OCH2Ph, ciano, CF3, F, Cl, Br, I, nitro, -OCF3, -SCF3, -ORC, -SRC, -S(O)RC, -SO2RC, -C(O)RC, fenilo, bencilo, fenetilo, -C(O)NRaRb, -C(O)ORc, -NRaRb, -CH2NRaRb o -CH2ORc; donde cada uno de Ra, Rb y Rc se selecciona, independientemente de otras asignaciones de sustituyentes, de H, alquilo C1-4, cicloalquilo C3-6, fenilo, (cicloalquil-C3-6)alquilo C1-2, bencilo y fenetilo, o Ra y Rb tomados junto con el nitrógeno al cual se encuentran unidos, forman un anillo heterocíclico de 4-7 miembros HetCyc1, donde dicho anillo HetCyc1 posee 0 ó 1 heteroátomos adicionales seleccionados de O, S, >NH y >Nalquilo C1-6 y donde cualquier resto fenilo, fenetilo, bencilo, alquilo o cicloalquilo en cualquiera de dichos R1-4, Ra, Rb, Rc y dicho anillo HetCyc1 está sustituido opcionalmente, e independientemente de otras asignaciones de sustituyentes, con 1, 2 ó 3 sustituyentes seleccionados de alquilo C1-3, halo, hidroxi, amino y alcoxi C1-3; cada uno de R5-7 es, independientemente de otras asignaciones de sustituyentes, H, alquilo C1-6, F, Cl, Br, I, CF3, -OCF3, - ORC, -SRC, -S(O)RC, -SO2RC, alcoxi C1-4, ciano, nitro, -C(O)NRaRb, -C(O)fenilo, -C(O)-alquilo C1-6, -S(O)-alquilo C1-4 o -SO2-alquilo C1-4; o, R5 y R6 para un compuesto de fórmula (1) tomados junto con los átomos de carbono a los que están unidos forman una estructura cíclica Cyc1 seleccionada de arilo, heteroarilo, carbociclo de 5 ó 6 miembros y heterociclo de 5 ó 6 miembros con 1 ó 2 heteroátomos, donde dicha estructura cíclica Cyc1 está sustituida, independientemente de otras asignaciones de sustituyentes, con 0, 1 ó 2 sustituyentes seleccionados de alquilo C1-3, halo, hidroxi, amino y alcoxi C1-3; o R7 y R6 para un compuesto de fórmula (2) tomados junto con los átomos de carbono a los que están unidos forman una estructura cíclica Cyc2 seleccionada de arilo, heteroarilo, carbociclo de 5 ó 6 miembros y heterociclo de 5 ó 6 miembros con 1 ó 2 heteroátomos, donde dicha estructura cíclica Cyc2 está sustituida, independientemente de otras asignaciones de sustituyentes, con 0, 1 ó 2 sustituyentes seleccionados de alquilo C1-3, halo, hidroxi, amino y alcoxi C1-3; R8 es, independientemente de otras asignaciones de sustituyentes, H o alquilo C1-6, o R9 y R10 tomados juntos forman una estructura cíclica de 5-6 miembros Cyc3, donde dicha estructura cíclica Cyc3 es un carbociclo de 5 ó 6 miembros o un heterociclo de 5 ó 6 miembros con 1 ó 2 heteroátomos y donde dicha estructura cíclica Cyc3 está sustituida, independientemente de otras asignaciones de sustituyentes, con 0, 1 ó 2 sustituyentes seleccionados de alquilo C1-3, halo, hidroxi, amino y alcoxi C1-3; R11 es H o alquilo C1-4; cada uno de R12 y R13 es, independientemente de otras asignaciones de sustituyentes, H, o alquilo C1-4; o, cuando Y es CR12R13, R12 y R13 tomados junto con el miembro de carbono al cual se encuentran unidos forman una estructura cíclica Cyc4 sustituida opcionalmente, donde dicha estructura cíclica Cyc4 es un carbociclo de 3 a 6 miembros o un heterociclo de 3 a 6 miembros con 0 o 1 heteroátomos adicionales, o CR12R13 es C=O; R14 es, H, alquilo C1-4, OH o alcoxi C1-4; un enantiómero, diastereómero, racemato del mismo, o una sal, amida o éster aceptable para uso farmacéutico del mismo; siempre que: cuando Y es O ó NR12, entonces Z sea CR14 y R8 no sea OH o alcoxi C1-4; cuando Z es N, Y sea CR12R13; y ninguno de R1 o R4 sea C(O)NH2.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US50723603P | 2003-09-30 | 2003-09-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR045955A1 true AR045955A1 (es) | 2005-11-16 |
Family
ID=38952593
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP040103534A AR045955A1 (es) | 2003-09-30 | 2004-09-29 | Compuestos benzoimidazolicos |
Country Status (21)
| Country | Link |
|---|---|
| US (10) | US7432378B2 (es) |
| EP (1) | EP1673348B1 (es) |
| JP (1) | JP2007508011A (es) |
| KR (1) | KR20060097024A (es) |
| CN (1) | CN1886380B (es) |
| AR (1) | AR045955A1 (es) |
| AT (1) | ATE427303T1 (es) |
| AU (1) | AU2004286933B2 (es) |
| BR (1) | BRPI0414918A (es) |
| CA (1) | CA2540704A1 (es) |
| DE (1) | DE602004020364D1 (es) |
| ES (1) | ES2323178T3 (es) |
| HR (1) | HRP20060126A2 (es) |
| IL (1) | IL174677A0 (es) |
| NO (1) | NO20061950L (es) |
| NZ (1) | NZ546259A (es) |
| PT (1) | PT1673348E (es) |
| RU (1) | RU2006110561A (es) |
| TW (1) | TW200526637A (es) |
| WO (1) | WO2005044807A2 (es) |
| ZA (1) | ZA200603411B (es) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1673348B1 (en) * | 2003-09-30 | 2009-04-01 | Janssen Pharmaceutica N.V. | Benzoimidazole compounds |
| UA89226C2 (en) | 2004-03-25 | 2010-01-11 | Янссен Фармацевтика Н.В. | Imidazole compounds |
| US7250427B2 (en) | 2004-06-30 | 2007-07-31 | Janssen Pharmaceutica, N.V. | Aryl-substituted benzimidazole and imidazopyridine ethers |
| CA2609716C (en) | 2005-05-26 | 2014-10-14 | Tibotec Pharmaceuticals Ltd. | Process for preparing 4-[(1,6-dihydro-6-oxo-2-pyrimidinyl)amino]benzonitrile |
| AU2006264649A1 (en) * | 2005-06-30 | 2007-01-11 | Prosidion Limited | GPCR agonists |
| CA2627722A1 (en) * | 2005-10-31 | 2007-06-21 | Merck & Co., Inc. | Cetp inhibitors |
| GB0525068D0 (en) | 2005-12-08 | 2006-01-18 | Novartis Ag | Organic compounds |
| JPWO2007069565A1 (ja) * | 2005-12-12 | 2009-05-21 | 小野薬品工業株式会社 | 二環式複素環化合物 |
| DE602007008859D1 (de) * | 2006-03-31 | 2010-10-14 | Janssen Pharmaceutica Nv | Benzoimidazol-2-yl pyridine als modulatoren des histamin-h4-rezeptors |
| DK2007752T3 (da) * | 2006-03-31 | 2010-11-15 | Janssen Pharmaceutica Nv | Benzimidazol-2-yl-pyrimidiner og -pyraziner som modulatorer af histamin H4-receptoren |
| US20090069343A1 (en) * | 2006-04-10 | 2009-03-12 | Dunford Paul J | Combination Histamine H1R and H4R Antagonist Therapy for Treating Pruritus |
| FR2903311B1 (fr) * | 2006-07-10 | 2012-06-15 | Centre Nat Rech Scient | Utilisation de ligands du recepteur h4 de l'histamine pour proteger les progeniteurs hematopoietiques contre la toxicite hematologique des agents chimiotherapeutiques |
| US7985745B2 (en) | 2006-10-02 | 2011-07-26 | Abbott Laboratories | Method for pain treatment |
| US8084466B2 (en) | 2007-12-18 | 2011-12-27 | Janssen Pharmaceutica Nv | Bicyclic heteroaryl-substituted imidazoles as modulators of the histamine H4 receptor |
| EP2077263A1 (en) | 2008-01-02 | 2009-07-08 | Vereniging voor christelijk hoger onderwijs, wetenschappelijk onderzoek en patiëntenzorg | Quinazolines and related heterocyclic compounds and their therapeutic use |
| NZ603069A (en) | 2008-06-12 | 2013-08-30 | Janssen Pharmaceutica Nv | Use of histamine h4 antagonist for the treatment of post-operative adhesions |
| US9371311B2 (en) | 2008-06-30 | 2016-06-21 | Janssen Pharmaceutica Nv | Benzoimidazol-2-yl pyrimidine derivatives |
| AU2009267159B2 (en) | 2008-06-30 | 2014-05-15 | Janssen Pharmaceutica Nv | Process for the preparation of benzoimidazol-2-yl pyrimidine derivatives |
| EP2350032B1 (en) | 2008-09-26 | 2016-05-25 | Eisai R&D Management Co., Ltd. | Benzoxazole compounds and methods of use |
| BRPI0919816A2 (pt) * | 2008-09-26 | 2019-09-24 | Eisai R&D Man Co Ltd | uso compostos benzoxazólicos no tratamento de malária |
| EP2201982A1 (en) | 2008-12-24 | 2010-06-30 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Histamine H4 receptor antagonists for the treatment of vestibular disorders |
| US8349852B2 (en) | 2009-01-13 | 2013-01-08 | Novartis Ag | Quinazolinone derivatives useful as vanilloid antagonists |
| IT1395137B1 (it) * | 2009-08-05 | 2012-09-05 | Spider Biotech S R L | Nuovi peptidi antipatogeni |
| TW201111378A (en) | 2009-09-11 | 2011-04-01 | Bayer Schering Pharma Ag | Substituted (heteroarylmethyl) thiohydantoins |
| JP2013518085A (ja) | 2010-02-01 | 2013-05-20 | ノバルティス アーゲー | ＣＲＦ−１受容体アンタゴニストとしてのピラゾロ［５，１ｂ］オキサゾール誘導体 |
| WO2011092293A2 (en) | 2010-02-01 | 2011-08-04 | Novartis Ag | Cyclohexyl amide derivatives as crf receptor antagonists |
| ES2527849T3 (es) | 2010-02-02 | 2015-01-30 | Novartis Ag | Derivados de ciclohexilamida como antagonistas del receptor de CRF |
| EP2447263A1 (en) * | 2010-09-27 | 2012-05-02 | Bioprojet | Benzazole derivatives as histamine H4 receptor ligands |
| AR086554A1 (es) | 2011-05-27 | 2014-01-08 | Novartis Ag | Derivados de la piperidina 3-espirociclica como agonistas de receptores de la ghrelina |
| DE102011122420B4 (de) | 2011-12-24 | 2016-07-28 | Volkswagen Aktiengesellschaft | Verfahren zur Feststellung der Spannungsfreiheit in einem elektrischen Hochvolt-System und ein elektrisches Hochvolt-System |
| EP2852591A1 (en) | 2012-05-03 | 2015-04-01 | Novartis AG | L-malate salt of 2, 7 - diaza - spiro [4.5]dec- 7 - yle derivatives and crystalline forms thereof as ghrelin receptor agonists |
| EP2671870A1 (en) * | 2012-06-05 | 2013-12-11 | Bioprojet | Novel (aza)benzhydryl ether derivatives, their process of preparation and their use as H4-receptor ligands for therapeutical applications |
| EP2858647B1 (en) | 2012-06-08 | 2018-05-23 | Sensorion | H4 receptor inhibitors for treating tinnitus |
| CN105025898B (zh) | 2013-03-06 | 2018-01-23 | 詹森药业有限公司 | 组胺h4受体的苯并咪唑‑2‑基嘧啶调节剂 |
| AU2019273559B2 (en) * | 2018-05-22 | 2024-01-18 | Nihon Nohyaku Co., Ltd. | Benzimidazole compound or salt thereof, agricultural and horticultural insecticidal and acaricidal agent containing said compound, and method for using same |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2587029B1 (fr) * | 1985-09-11 | 1987-10-30 | Synthelabo | Derives de benzimidazole, leur preparation et leur application en therapeutique |
| WO1998006703A1 (en) * | 1996-08-14 | 1998-02-19 | Warner-Lambert Company | 2-phenyl benzimidazole derivatives as mcp-1 antagonists |
| JP2002528531A (ja) | 1998-11-03 | 2002-09-03 | ビーエーエスエフ アクチェンゲゼルシャフト | 置換２−フェニルベンズイミダゾール、その製造法および使用 |
| DE19920936A1 (de) * | 1999-05-07 | 2000-11-09 | Basf Ag | Heterozyklisch substituierte Benzimidazole, deren Herstellung und Anwendung |
| JP4544820B2 (ja) * | 2001-03-09 | 2010-09-15 | オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド | 複素環化合物 |
| EP1673348B1 (en) * | 2003-09-30 | 2009-04-01 | Janssen Pharmaceutica N.V. | Benzoimidazole compounds |
-
2004
- 2004-09-29 EP EP04816894A patent/EP1673348B1/en active Active
- 2004-09-29 AU AU2004286933A patent/AU2004286933B2/en not_active Ceased
- 2004-09-29 CN CN2004800354157A patent/CN1886380B/zh not_active Expired - Fee Related
- 2004-09-29 AR ARP040103534A patent/AR045955A1/es not_active Application Discontinuation
- 2004-09-29 WO PCT/US2004/031855 patent/WO2005044807A2/en active Application Filing
- 2004-09-29 RU RU2006110561/04A patent/RU2006110561A/ru not_active Application Discontinuation
- 2004-09-29 KR KR1020067008435A patent/KR20060097024A/ko not_active Application Discontinuation
- 2004-09-29 PT PT04816894T patent/PT1673348E/pt unknown
- 2004-09-29 DE DE602004020364T patent/DE602004020364D1/de active Active
- 2004-09-29 NZ NZ546259A patent/NZ546259A/en unknown
- 2004-09-29 ES ES04816894T patent/ES2323178T3/es active Active
- 2004-09-29 JP JP2006534031A patent/JP2007508011A/ja active Pending
- 2004-09-29 US US10/952,989 patent/US7432378B2/en active Active
- 2004-09-29 AT AT04816894T patent/ATE427303T1/de not_active IP Right Cessation
- 2004-09-29 CA CA002540704A patent/CA2540704A1/en not_active Abandoned
- 2004-09-29 BR BRPI0414918-1A patent/BRPI0414918A/pt not_active IP Right Cessation
- 2004-09-29 TW TW093129453A patent/TW200526637A/zh unknown
-
2006
- 2006-03-30 IL IL174677A patent/IL174677A0/en unknown
- 2006-03-30 HR HR20060126A patent/HRP20060126A2/xx not_active Application Discontinuation
- 2006-04-28 ZA ZA200603411A patent/ZA200603411B/en unknown
- 2006-05-02 NO NO20061950A patent/NO20061950L/no not_active Application Discontinuation
-
2008
- 2008-08-26 US US12/229,890 patent/US7723359B2/en active Active
- 2008-08-26 US US12/229,779 patent/US20090270611A1/en not_active Abandoned
- 2008-08-26 US US12/229,888 patent/US7705143B2/en active Active
- 2008-08-26 US US12/229,892 patent/US7662966B2/en active Active
- 2008-08-26 US US12/229,891 patent/US20090281307A1/en not_active Abandoned
- 2008-08-26 US US12/229,781 patent/US7723526B2/en active Active
- 2008-08-26 US US12/229,886 patent/US7723527B2/en active Active
- 2008-08-26 US US12/229,882 patent/US7705149B2/en active Active
- 2008-10-23 US US12/257,362 patent/US20090247508A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR045955A1 (es) | Compuestos benzoimidazolicos | |
| ES2525763T3 (es) | Derivados del ácido fenilalcanoico sustituido y sus usos para el tratamiento de enfermedades respiratorias | |
| AR058546A1 (es) | Derivados de 2- adamantilurea como inhibidores selectivos de 11 beta - hsd1 | |
| AR065015A1 (es) | Derivados de antranilamida, composiciones farmaceuticas que los contienen, y usos para el tratamiento del cancer | |
| AR053092A1 (es) | Compuestos derivados de acido fenoxiacetico y compuestos intermediarios de sintesis | |
| AR085960A1 (es) | 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2 | |
| CL2008002654A1 (es) | Compuestos derivados de 1,2,4,5-tetrahidro-3h-benzazepinas, bloqueadores de los canales hcn; procedimiento de preparacion de dichos compuestos; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar cardiopatias isquemicas, insuficiencias cardiacas tanto sistolicas como diastolicas, entre otras. | |
| AR051995A1 (es) | Derivados de tieno-piridina como intensificadores alostericos de gaba -b | |
| CY1108908T1 (el) | Ενωσεις κινολινονης - καρβοξαμιδης ως αγωνιστες υποδοχεων 5-ητ4 | |
| AR054560A1 (es) | Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer | |
| AR086983A1 (es) | Derivados de azetidinil fenil, piridil o pirazinil carboxamida como inhibidores de jak | |
| AR040773A1 (es) | Pirazoles utiles como inhibidores de gsk-3 | |
| PE20130375A1 (es) | Compuestos de triazolopiridinas y triazolopirazinas inhibidores de c-met y composiciones de los mismos | |
| RS52126B (en) | AZABIFENYLAMINOBENZOIC ACID DERIVATIVES AS DYHydroOROTATE DEHYDROGENASE INHIBITORS (DHODH) | |
| AR065300A1 (es) | Compuestos quimicos derivados de 1,2-pirazol | |
| AR077463A1 (es) | Derivados de imidazo[1, 2 - a]pirazina y su uso en medicamentos para el tratamiento de enfermedades parasitarias | |
| AR059184A1 (es) | Derivados de sulfonamidas, su preparacion y su aplicacion en tarapeutica | |
| AR056892A1 (es) | Derivados de cinolin-3-carboxamida, metodos para su preparacion, composiciones farmaceuticas que los contienen y su uso en la fabricacion de medicamentos para el tratamiento de enfermedades mediadas por la modulacion del receptor gabaa | |
| AR075583A1 (es) | Derivados de isoxazol/o-piridina con eslabon etilo o etenilo | |
| AR053554A1 (es) | Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos | |
| CO5690551A2 (es) | Derivados de tetrazol y metodos para el tratamiento con los mismos de trastornos relacionados con el metabolismo | |
| NI201000049A (es) | Método para producir 2'-desoxi-5-azacitidina (decitabina) | |
| AR061835A1 (es) | Derivados tetraciclicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen | |
| CO2020001326A2 (es) | Nuevos compuestos heterocíclicos como inhibidores de cdk8/19 | |
| EA200970793A1 (ru) | Модуляторы рецепторов, активируемых пролифераторами пероксисом |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |